nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—PTGS1—Sulfasalazine—ankylosing spondylitis	0.108	0.247	CbGbCtD
Bortezomib—CYP1A1—Dexamethasone—ankylosing spondylitis	0.054	0.123	CbGbCtD
Bortezomib—CYP2C19—Prednisone—ankylosing spondylitis	0.0418	0.0957	CbGbCtD
Bortezomib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.0334	0.0763	CbGbCtD
Bortezomib—CYP2C8—Dexamethasone—ankylosing spondylitis	0.0311	0.0712	CbGbCtD
Bortezomib—CYP2C19—Dexamethasone—ankylosing spondylitis	0.0261	0.0597	CbGbCtD
Bortezomib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0253	0.0578	CbGbCtD
Bortezomib—CYP2C9—Dexamethasone—ankylosing spondylitis	0.0217	0.0496	CbGbCtD
Bortezomib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0217	0.0496	CbGbCtD
Bortezomib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0214	0.049	CbGbCtD
Bortezomib—CYP3A4—Prednisone—ankylosing spondylitis	0.0202	0.0462	CbGbCtD
Bortezomib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0199	0.0454	CbGbCtD
Bortezomib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0126	0.0289	CbGbCtD
Bortezomib—PSMB8—Balsalazide—Sulfasalazine—ankylosing spondylitis	0.00182	0.152	CbGdCrCtD
Bortezomib—PSMB8—Antigen processing-Cross presentation—HLA-A—ankylosing spondylitis	0.000769	0.00397	CbGpPWpGaD
Bortezomib—PSMA1—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.00075	0.00387	CbGpPWpGaD
Bortezomib—PSMD1—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.000746	0.00385	CbGpPWpGaD
Bortezomib—PSMD2—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.000743	0.00384	CbGpPWpGaD
Bortezomib—PSMA1—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.000716	0.00369	CbGpPWpGaD
Bortezomib—PSMD1—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.000712	0.00368	CbGpPWpGaD
Bortezomib—PSMD2—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.000709	0.00366	CbGpPWpGaD
Bortezomib—PSMA1—B Cell Activation—CD79A—ankylosing spondylitis	0.000702	0.00363	CbGpPWpGaD
Bortezomib—PSMD1—B Cell Activation—CD79A—ankylosing spondylitis	0.000699	0.00361	CbGpPWpGaD
Bortezomib—PSMD2—B Cell Activation—CD79A—ankylosing spondylitis	0.000696	0.00359	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000694	0.00358	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—KIR3DL1—ankylosing spondylitis	0.000683	0.00352	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—KIR3DL1—ankylosing spondylitis	0.000679	0.00351	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—KIR3DL1—ankylosing spondylitis	0.000676	0.00349	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000646	0.00334	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000643	0.00332	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00064	0.00331	CbGpPWpGaD
Bortezomib—PSMB5—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.000568	0.00294	CbGpPWpGaD
Bortezomib—PSMB2—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.000568	0.00294	CbGpPWpGaD
Bortezomib—PSMB1—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.000568	0.00294	CbGpPWpGaD
Bortezomib—PSMB8—Class I MHC mediated antigen processing & presentation—HLA-C—ankylosing spondylitis	0.00056	0.00289	CbGpPWpGaD
Bortezomib—PTGS1—Overview of nanoparticle effects—TNF—ankylosing spondylitis	0.000556	0.00287	CbGpPWpGaD
Bortezomib—PSMB1—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.000542	0.0028	CbGpPWpGaD
Bortezomib—PSMB5—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.000542	0.0028	CbGpPWpGaD
Bortezomib—PSMB2—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.000542	0.0028	CbGpPWpGaD
Bortezomib—PSMB8—Host Interactions of HIV factors—HLA-A—ankylosing spondylitis	0.000535	0.00276	CbGpPWpGaD
Bortezomib—PSMB2—B Cell Activation—CD79A—ankylosing spondylitis	0.000532	0.00275	CbGpPWpGaD
Bortezomib—PSMB5—B Cell Activation—CD79A—ankylosing spondylitis	0.000532	0.00275	CbGpPWpGaD
Bortezomib—PSMB1—B Cell Activation—CD79A—ankylosing spondylitis	0.000532	0.00275	CbGpPWpGaD
Bortezomib—PSMB8—B Cell Activation—CD79A—ankylosing spondylitis	0.000525	0.00271	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KIR3DL1—ankylosing spondylitis	0.000517	0.00267	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KIR3DL1—ankylosing spondylitis	0.000517	0.00267	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KIR3DL1—ankylosing spondylitis	0.000517	0.00267	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HLA-C—ankylosing spondylitis	0.000515	0.00266	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KIR3DL1—ankylosing spondylitis	0.00051	0.00263	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00049	0.00253	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00049	0.00253	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.00049	0.00253	CbGpPWpGaD
Bortezomib—PSMD2—Fluticasone Propionate—Methylprednisolone—ankylosing spondylitis	0.00049	0.041	CbGdCrCtD
Bortezomib—PSMB8—Medrysone—Methylprednisolone—ankylosing spondylitis	0.000487	0.0407	CbGdCrCtD
Bortezomib—PSMB8—Adaptive Immune System—ERAP1—ankylosing spondylitis	0.000483	0.00249	CbGpPWpGaD
Bortezomib—PSMD2—Fluticasone Propionate—Betamethasone—ankylosing spondylitis	0.000482	0.0403	CbGdCrCtD
Bortezomib—PSMD2—Fluticasone Propionate—Dexamethasone—ankylosing spondylitis	0.000482	0.0403	CbGdCrCtD
Bortezomib—PSMA1—Disease—ANTXR2—ankylosing spondylitis	0.000478	0.00247	CbGpPWpGaD
Bortezomib—PSMD1—Disease—ANTXR2—ankylosing spondylitis	0.000475	0.00245	CbGpPWpGaD
Bortezomib—PSMD2—Disease—ANTXR2—ankylosing spondylitis	0.000473	0.00244	CbGpPWpGaD
Bortezomib—PSMD2—Fluticasone Propionate—Triamcinolone—ankylosing spondylitis	0.000471	0.0394	CbGdCrCtD
Bortezomib—PSMA1—HIV Infection—HLA-A—ankylosing spondylitis	0.000465	0.0024	CbGpPWpGaD
Bortezomib—PSMD1—HIV Infection—HLA-A—ankylosing spondylitis	0.000463	0.00239	CbGpPWpGaD
Bortezomib—PSMD2—HIV Infection—HLA-A—ankylosing spondylitis	0.00046	0.00238	CbGpPWpGaD
Bortezomib—PSMB8—Interferon Signaling—HLA-B—ankylosing spondylitis	0.000456	0.00236	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IL1RN—ankylosing spondylitis	0.000447	0.00231	CbGpPWpGaD
Bortezomib—PSMA1—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.000444	0.00229	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—ankylosing spondylitis	0.000443	0.00229	CbGpPWpGaD
Bortezomib—PSMD1—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.000441	0.00228	CbGpPWpGaD
Bortezomib—PSMD2—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.000439	0.00227	CbGpPWpGaD
Bortezomib—PSMB8—Medrysone—Prednisolone—ankylosing spondylitis	0.000434	0.0363	CbGdCrCtD
Bortezomib—PSMB8—Interferon Signaling—HLA-A—ankylosing spondylitis	0.000423	0.00218	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL1R2—ankylosing spondylitis	0.000414	0.00214	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL1R2—ankylosing spondylitis	0.000412	0.00213	CbGpPWpGaD
Bortezomib—PSMA1—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000411	0.00212	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL1R2—ankylosing spondylitis	0.00041	0.00212	CbGpPWpGaD
Bortezomib—PSMD1—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000409	0.00211	CbGpPWpGaD
Bortezomib—PSMD2—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000407	0.0021	CbGpPWpGaD
Bortezomib—PSMD2—TNF alpha Signaling Pathway—TNF—ankylosing spondylitis	0.000394	0.00203	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—ERAP1—ankylosing spondylitis	0.000392	0.00202	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—ERAP1—ankylosing spondylitis	0.00039	0.00201	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—ERAP1—ankylosing spondylitis	0.000388	0.00201	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000371	0.00192	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000369	0.00191	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000368	0.0019	CbGpPWpGaD
Bortezomib—PSMB2—Disease—ANTXR2—ankylosing spondylitis	0.000362	0.00187	CbGpPWpGaD
Bortezomib—PSMB1—Disease—ANTXR2—ankylosing spondylitis	0.000362	0.00187	CbGpPWpGaD
Bortezomib—PSMB5—Disease—ANTXR2—ankylosing spondylitis	0.000362	0.00187	CbGpPWpGaD
Bortezomib—PTGS1—Selenium Micronutrient Network—CRP—ankylosing spondylitis	0.00036	0.00186	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CARD9—ankylosing spondylitis	0.000359	0.00185	CbGpPWpGaD
Bortezomib—PSMB8—Disease—ANTXR2—ankylosing spondylitis	0.000357	0.00184	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CARD9—ankylosing spondylitis	0.000357	0.00184	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CARD9—ankylosing spondylitis	0.000355	0.00183	CbGpPWpGaD
Bortezomib—PSMB8—Fluorometholone—Methylprednisolone—ankylosing spondylitis	0.000353	0.0295	CbGdCrCtD
Bortezomib—PSMB2—HIV Infection—HLA-A—ankylosing spondylitis	0.000352	0.00182	CbGpPWpGaD
Bortezomib—PSMB1—HIV Infection—HLA-A—ankylosing spondylitis	0.000352	0.00182	CbGpPWpGaD
Bortezomib—PSMB5—HIV Infection—HLA-A—ankylosing spondylitis	0.000352	0.00182	CbGpPWpGaD
Bortezomib—PSMB8—HIV Infection—HLA-A—ankylosing spondylitis	0.000347	0.00179	CbGpPWpGaD
Bortezomib—PSMB8—Fluorometholone—Dexamethasone—ankylosing spondylitis	0.000347	0.029	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Betamethasone—ankylosing spondylitis	0.000347	0.029	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Triamcinolone—ankylosing spondylitis	0.000339	0.0284	CbGdCrCtD
Bortezomib—PSMB2—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.000336	0.00174	CbGpPWpGaD
Bortezomib—PSMB1—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.000336	0.00174	CbGpPWpGaD
Bortezomib—PSMB5—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.000336	0.00174	CbGpPWpGaD
Bortezomib—PSMB8—Class I MHC mediated antigen processing & presentation—HLA-B—ankylosing spondylitis	0.000331	0.00171	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IL1A—ankylosing spondylitis	0.000322	0.00166	CbGpPWpGaD
Bortezomib—PSMB8—Fluorometholone—Prednisone—ankylosing spondylitis	0.000322	0.0269	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Prednisolone—ankylosing spondylitis	0.000314	0.0263	CbGdCrCtD
Bortezomib—PSMB2—Immune System—IL1R2—ankylosing spondylitis	0.000313	0.00162	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL1R2—ankylosing spondylitis	0.000313	0.00162	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL1R2—ankylosing spondylitis	0.000313	0.00162	CbGpPWpGaD
Bortezomib—PSMB2—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000311	0.00161	CbGpPWpGaD
Bortezomib—PSMB5—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000311	0.00161	CbGpPWpGaD
Bortezomib—PSMB1—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000311	0.00161	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL1R2—ankylosing spondylitis	0.000309	0.0016	CbGpPWpGaD
Bortezomib—PSMB8—Class I MHC mediated antigen processing & presentation—HLA-A—ankylosing spondylitis	0.000307	0.00159	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HLA-B—ankylosing spondylitis	0.000305	0.00157	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—ERAP1—ankylosing spondylitis	0.000297	0.00153	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—ERAP1—ankylosing spondylitis	0.000297	0.00153	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—ERAP1—ankylosing spondylitis	0.000297	0.00153	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—ERAP1—ankylosing spondylitis	0.000293	0.00151	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000283	0.00146	CbGpPWpGaD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—HLA-A—ankylosing spondylitis	0.000282	0.00146	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000282	0.00146	CbGpPWpGaD
Bortezomib—PSMA1—Disease—B3GNT2—ankylosing spondylitis	0.000281	0.00145	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000281	0.00145	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000281	0.00145	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000281	0.00145	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.00028	0.00145	CbGpPWpGaD
Bortezomib—PSMD1—Disease—B3GNT2—ankylosing spondylitis	0.00028	0.00145	CbGpPWpGaD
Bortezomib—PSMD2—Disease—B3GNT2—ankylosing spondylitis	0.000279	0.00144	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HLA-C—ankylosing spondylitis	0.000277	0.00143	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CARD9—ankylosing spondylitis	0.000272	0.0014	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CARD9—ankylosing spondylitis	0.000272	0.0014	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CARD9—ankylosing spondylitis	0.000272	0.0014	CbGpPWpGaD
Bortezomib—PSMB8—Diflorasone—Methylprednisolone—ankylosing spondylitis	0.000269	0.0225	CbGdCrCtD
Bortezomib—PSMB8—Immune System—CARD9—ankylosing spondylitis	0.000268	0.00138	CbGpPWpGaD
Bortezomib—PSMB8—Diflorasone—Dexamethasone—ankylosing spondylitis	0.000264	0.0221	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Betamethasone—ankylosing spondylitis	0.000264	0.0221	CbGdCrCtD
Bortezomib—PSMA1—Apoptosis—TNF—ankylosing spondylitis	0.000262	0.00135	CbGpPWpGaD
Bortezomib—PSMD1—Apoptosis—TNF—ankylosing spondylitis	0.000261	0.00135	CbGpPWpGaD
Bortezomib—PSMD2—Apoptosis—TNF—ankylosing spondylitis	0.000259	0.00134	CbGpPWpGaD
Bortezomib—PSMB8—Diflorasone—Triamcinolone—ankylosing spondylitis	0.000258	0.0216	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000248	0.0208	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000248	0.0208	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisone—ankylosing spondylitis	0.000245	0.0205	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000244	0.0204	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000244	0.0204	CbGdCrCtD
Bortezomib—PSMB8—Diflorasone—Prednisolone—ankylosing spondylitis	0.000239	0.02	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000239	0.02	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000239	0.02	CbGdCrCtD
Bortezomib—PSMA1—Metabolism—B3GNT2—ankylosing spondylitis	0.000236	0.00122	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—B3GNT2—ankylosing spondylitis	0.000235	0.00121	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—B3GNT2—ankylosing spondylitis	0.000234	0.00121	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000231	0.00119	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.00023	0.00119	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000229	0.00118	CbGpPWpGaD
Bortezomib—PSMD2—Dexamethasone—Prednisone—ankylosing spondylitis	0.000227	0.019	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisone—ankylosing spondylitis	0.000227	0.019	CbGdCrCtD
Bortezomib—PSMA1—Immune System—HLA-C—ankylosing spondylitis	0.000225	0.00116	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HLA-C—ankylosing spondylitis	0.000224	0.00116	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—HLA-C—ankylosing spondylitis	0.000223	0.00115	CbGpPWpGaD
Bortezomib—PSMD2—Betamethasone—Prednisolone—ankylosing spondylitis	0.000221	0.0185	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000221	0.0185	CbGdCrCtD
Bortezomib—PSMA1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.00022	0.00113	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000218	0.00113	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000217	0.00112	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000215	0.00111	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000215	0.00111	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000215	0.00111	CbGpPWpGaD
Bortezomib—PSMB5—Disease—B3GNT2—ankylosing spondylitis	0.000213	0.0011	CbGpPWpGaD
Bortezomib—PSMB2—Disease—B3GNT2—ankylosing spondylitis	0.000213	0.0011	CbGpPWpGaD
Bortezomib—PSMB1—Disease—B3GNT2—ankylosing spondylitis	0.000213	0.0011	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CD79A—ankylosing spondylitis	0.000212	0.00109	CbGpPWpGaD
Bortezomib—PSMB8—Disease—B3GNT2—ankylosing spondylitis	0.00021	0.00109	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000203	0.00105	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000202	0.00105	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000201	0.00104	CbGpPWpGaD
Bortezomib—PSMB5—Apoptosis—TNF—ankylosing spondylitis	0.000198	0.00102	CbGpPWpGaD
Bortezomib—PSMB2—Apoptosis—TNF—ankylosing spondylitis	0.000198	0.00102	CbGpPWpGaD
Bortezomib—PSMB1—Apoptosis—TNF—ankylosing spondylitis	0.000198	0.00102	CbGpPWpGaD
Bortezomib—PSMB8—Apoptosis—TNF—ankylosing spondylitis	0.000196	0.00101	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—IL1RN—ankylosing spondylitis	0.000196	0.00101	CbGpPWpGaD
Bortezomib—Insomnia—Prednisolone—ankylosing spondylitis	0.000195	0.000547	CcSEcCtD
Bortezomib—Shock—Methylprednisolone—ankylosing spondylitis	0.000195	0.000546	CcSEcCtD
Bortezomib—PSMD1—Immune System—IL1RN—ankylosing spondylitis	0.000195	0.00101	CbGpPWpGaD
Bortezomib—Hepatobiliary disease—Methotrexate—ankylosing spondylitis	0.000194	0.000545	CcSEcCtD
Bortezomib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.000194	0.000544	CcSEcCtD
Bortezomib—Loss of consciousness—Betamethasone—ankylosing spondylitis	0.000194	0.000544	CcSEcCtD
Bortezomib—Loss of consciousness—Dexamethasone—ankylosing spondylitis	0.000194	0.000544	CcSEcCtD
Bortezomib—Epistaxis—Methotrexate—ankylosing spondylitis	0.000194	0.000543	CcSEcCtD
Bortezomib—Paraesthesia—Prednisolone—ankylosing spondylitis	0.000194	0.000543	CcSEcCtD
Bortezomib—Tachycardia—Triamcinolone—ankylosing spondylitis	0.000194	0.000543	CcSEcCtD
Bortezomib—PSMD2—Immune System—IL1RN—ankylosing spondylitis	0.000194	0.001	CbGpPWpGaD
Bortezomib—Mental disorder—Prednisone—ankylosing spondylitis	0.000193	0.000542	CcSEcCtD
Bortezomib—Tachycardia—Methylprednisolone—ankylosing spondylitis	0.000193	0.000542	CcSEcCtD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000193	0.000997	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000193	0.000997	CbGpPWpGaD
Bortezomib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000192	0.000539	CcSEcCtD
Bortezomib—Malnutrition—Prednisone—ankylosing spondylitis	0.000192	0.000539	CcSEcCtD
Bortezomib—Erythema—Prednisone—ankylosing spondylitis	0.000192	0.000539	CcSEcCtD
Bortezomib—Hyperhidrosis—Triamcinolone—ankylosing spondylitis	0.000192	0.000538	CcSEcCtD
Bortezomib—Hyperhidrosis—Methylprednisolone—ankylosing spondylitis	0.000192	0.000537	CcSEcCtD
Bortezomib—Convulsion—Dexamethasone—ankylosing spondylitis	0.000191	0.000536	CcSEcCtD
Bortezomib—Convulsion—Betamethasone—ankylosing spondylitis	0.000191	0.000536	CcSEcCtD
Bortezomib—Hypertension—Betamethasone—ankylosing spondylitis	0.000191	0.000534	CcSEcCtD
Bortezomib—Hypertension—Dexamethasone—ankylosing spondylitis	0.000191	0.000534	CcSEcCtD
Bortezomib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000188	0.000527	CcSEcCtD
Bortezomib—Myalgia—Betamethasone—ankylosing spondylitis	0.000188	0.000527	CcSEcCtD
Bortezomib—Anxiety—Dexamethasone—ankylosing spondylitis	0.000187	0.000525	CcSEcCtD
Bortezomib—Anxiety—Betamethasone—ankylosing spondylitis	0.000187	0.000525	CcSEcCtD
Bortezomib—Discomfort—Dexamethasone—ankylosing spondylitis	0.000186	0.00052	CcSEcCtD
Bortezomib—Discomfort—Betamethasone—ankylosing spondylitis	0.000186	0.00052	CcSEcCtD
Bortezomib—Haemoglobin—Methotrexate—ankylosing spondylitis	0.000185	0.00052	CcSEcCtD
Bortezomib—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000185	0.000519	CcSEcCtD
Bortezomib—Pain—Prednisolone—ankylosing spondylitis	0.000185	0.000517	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—ankylosing spondylitis	0.000185	0.000517	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—ankylosing spondylitis	0.000185	0.000517	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—ankylosing spondylitis	0.000182	0.000511	CcSEcCtD
Bortezomib—Vision blurred—Prednisone—ankylosing spondylitis	0.000181	0.000508	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—ankylosing spondylitis	0.000181	0.000507	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000181	0.000507	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.00018	0.000506	CcSEcCtD
Bortezomib—Oedema—Betamethasone—ankylosing spondylitis	0.00018	0.000505	CcSEcCtD
Bortezomib—Oedema—Dexamethasone—ankylosing spondylitis	0.00018	0.000505	CcSEcCtD
Bortezomib—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.00018	0.000505	CcSEcCtD
Bortezomib—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.00018	0.000505	CcSEcCtD
Bortezomib—Insomnia—Triamcinolone—ankylosing spondylitis	0.00018	0.000503	CcSEcCtD
Bortezomib—Insomnia—Methylprednisolone—ankylosing spondylitis	0.000179	0.000502	CcSEcCtD
Bortezomib—Infection—Dexamethasone—ankylosing spondylitis	0.000179	0.000501	CcSEcCtD
Bortezomib—Infection—Betamethasone—ankylosing spondylitis	0.000179	0.000501	CcSEcCtD
Bortezomib—PSMB1—Metabolism—B3GNT2—ankylosing spondylitis	0.000179	0.000923	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—B3GNT2—ankylosing spondylitis	0.000179	0.000923	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—B3GNT2—ankylosing spondylitis	0.000179	0.000923	CbGpPWpGaD
Bortezomib—Ill-defined disorder—Prednisone—ankylosing spondylitis	0.000178	0.0005	CcSEcCtD
Bortezomib—Paraesthesia—Triamcinolone—ankylosing spondylitis	0.000178	0.0005	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisolone—ankylosing spondylitis	0.000178	0.000499	CcSEcCtD
Bortezomib—Paraesthesia—Methylprednisolone—ankylosing spondylitis	0.000178	0.000498	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—ankylosing spondylitis	0.000178	0.000498	CcSEcCtD
Bortezomib—Anaemia—Prednisone—ankylosing spondylitis	0.000178	0.000498	CcSEcCtD
Bortezomib—Shock—Betamethasone—ankylosing spondylitis	0.000177	0.000497	CcSEcCtD
Bortezomib—Shock—Dexamethasone—ankylosing spondylitis	0.000177	0.000497	CcSEcCtD
Bortezomib—Dyspnoea—Triamcinolone—ankylosing spondylitis	0.000177	0.000496	CcSEcCtD
Bortezomib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000177	0.000495	CcSEcCtD
Bortezomib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000177	0.000495	CcSEcCtD
Bortezomib—Agitation—Prednisone—ankylosing spondylitis	0.000177	0.000495	CcSEcCtD
Bortezomib—Thrombocytopenia—Betamethasone—ankylosing spondylitis	0.000176	0.000494	CcSEcCtD
Bortezomib—Thrombocytopenia—Dexamethasone—ankylosing spondylitis	0.000176	0.000494	CcSEcCtD
Bortezomib—PSMB8—Metabolism—B3GNT2—ankylosing spondylitis	0.000176	0.00091	CbGpPWpGaD
Bortezomib—Tachycardia—Dexamethasone—ankylosing spondylitis	0.000176	0.000493	CcSEcCtD
Bortezomib—Tachycardia—Betamethasone—ankylosing spondylitis	0.000176	0.000493	CcSEcCtD
Bortezomib—Angioedema—Prednisone—ankylosing spondylitis	0.000176	0.000492	CcSEcCtD
Bortezomib—PSMB2—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000175	0.000903	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000175	0.000903	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000175	0.000903	CbGpPWpGaD
Bortezomib—Dyspepsia—Triamcinolone—ankylosing spondylitis	0.000175	0.00049	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000174	0.000489	CcSEcCtD
Bortezomib—Dyspepsia—Methylprednisolone—ankylosing spondylitis	0.000174	0.000489	CcSEcCtD
Bortezomib—Hyperhidrosis—Dexamethasone—ankylosing spondylitis	0.000174	0.000488	CcSEcCtD
Bortezomib—Hyperhidrosis—Betamethasone—ankylosing spondylitis	0.000174	0.000488	CcSEcCtD
Bortezomib—Malaise—Prednisone—ankylosing spondylitis	0.000173	0.000486	CcSEcCtD
Bortezomib—Vertigo—Prednisone—ankylosing spondylitis	0.000173	0.000484	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000172	0.000483	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—CD40LG—ankylosing spondylitis	0.000172	0.00089	CbGpPWpGaD
Bortezomib—Syncope—Prednisone—ankylosing spondylitis	0.000172	0.000483	CcSEcCtD
Bortezomib—Tinnitus—Methotrexate—ankylosing spondylitis	0.000172	0.000482	CcSEcCtD
Bortezomib—Anorexia—Betamethasone—ankylosing spondylitis	0.000172	0.000481	CcSEcCtD
Bortezomib—Anorexia—Dexamethasone—ankylosing spondylitis	0.000172	0.000481	CcSEcCtD
Bortezomib—PSMA1—Immune System—CD79A—ankylosing spondylitis	0.000172	0.000887	CbGpPWpGaD
Bortezomib—Urticaria—Prednisolone—ankylosing spondylitis	0.000172	0.000481	CcSEcCtD
Bortezomib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000171	0.00048	CcSEcCtD
Bortezomib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000171	0.00048	CcSEcCtD
Bortezomib—PSMD1—Immune System—CD79A—ankylosing spondylitis	0.000171	0.000883	CbGpPWpGaD
Bortezomib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000171	0.000479	CcSEcCtD
Bortezomib—PSMB5—Immune System—HLA-C—ankylosing spondylitis	0.000171	0.000881	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-C—ankylosing spondylitis	0.000171	0.000881	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HLA-C—ankylosing spondylitis	0.000171	0.000881	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CD79A—ankylosing spondylitis	0.00017	0.000878	CbGpPWpGaD
Bortezomib—Pain—Triamcinolone—ankylosing spondylitis	0.00017	0.000476	CcSEcCtD
Bortezomib—Loss of consciousness—Prednisone—ankylosing spondylitis	0.000169	0.000473	CcSEcCtD
Bortezomib—Hypotension—Betamethasone—ankylosing spondylitis	0.000168	0.000472	CcSEcCtD
Bortezomib—Hypotension—Dexamethasone—ankylosing spondylitis	0.000168	0.000472	CcSEcCtD
Bortezomib—PSMB8—Immune System—HLA-C—ankylosing spondylitis	0.000168	0.000869	CbGpPWpGaD
Bortezomib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000167	0.000469	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—ankylosing spondylitis	0.000167	0.000467	CcSEcCtD
Bortezomib—Convulsion—Prednisone—ankylosing spondylitis	0.000167	0.000467	CcSEcCtD
Bortezomib—PSMB1—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000166	0.000859	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000166	0.000859	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000166	0.000859	CbGpPWpGaD
Bortezomib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000166	0.000466	CcSEcCtD
Bortezomib—Hypertension—Prednisone—ankylosing spondylitis	0.000166	0.000465	CcSEcCtD
Bortezomib—Chills—Methotrexate—ankylosing spondylitis	0.000166	0.000464	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.000164	0.00046	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.000164	0.00046	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—HLA-B—ankylosing spondylitis	0.000164	0.000847	CbGpPWpGaD
Bortezomib—Arthralgia—Prednisone—ankylosing spondylitis	0.000164	0.000459	CcSEcCtD
Bortezomib—Myalgia—Prednisone—ankylosing spondylitis	0.000164	0.000459	CcSEcCtD
Bortezomib—Feeling abnormal—Triamcinolone—ankylosing spondylitis	0.000164	0.000458	CcSEcCtD
Bortezomib—Feeling abnormal—Methylprednisolone—ankylosing spondylitis	0.000163	0.000457	CcSEcCtD
Bortezomib—PTGS1—Selenium Micronutrient Network—TNF—ankylosing spondylitis	0.000163	0.000842	CbGpPWpGaD
Bortezomib—Anxiety—Prednisone—ankylosing spondylitis	0.000163	0.000457	CcSEcCtD
Bortezomib—Insomnia—Dexamethasone—ankylosing spondylitis	0.000163	0.000457	CcSEcCtD
Bortezomib—Insomnia—Betamethasone—ankylosing spondylitis	0.000163	0.000457	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000163	0.000455	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methylprednisolone—ankylosing spondylitis	0.000162	0.000454	CcSEcCtD
Bortezomib—Paraesthesia—Betamethasone—ankylosing spondylitis	0.000162	0.000453	CcSEcCtD
Bortezomib—Paraesthesia—Dexamethasone—ankylosing spondylitis	0.000162	0.000453	CcSEcCtD
Bortezomib—Discomfort—Prednisone—ankylosing spondylitis	0.000162	0.000453	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—ankylosing spondylitis	0.000162	0.000453	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000161	0.00045	CcSEcCtD
Bortezomib—Erythema—Methotrexate—ankylosing spondylitis	0.000161	0.00045	CcSEcCtD
Bortezomib—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000159	0.000446	CcSEcCtD
Bortezomib—Dyspepsia—Dexamethasone—ankylosing spondylitis	0.000159	0.000444	CcSEcCtD
Bortezomib—Dyspepsia—Betamethasone—ankylosing spondylitis	0.000159	0.000444	CcSEcCtD
Bortezomib—Urticaria—Triamcinolone—ankylosing spondylitis	0.000158	0.000442	CcSEcCtD
Bortezomib—Urticaria—Methylprednisolone—ankylosing spondylitis	0.000157	0.000441	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000157	0.000441	CcSEcCtD
Bortezomib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000157	0.00044	CcSEcCtD
Bortezomib—Oedema—Prednisone—ankylosing spondylitis	0.000157	0.00044	CcSEcCtD
Bortezomib—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000157	0.00044	CcSEcCtD
Bortezomib—Abdominal pain—Methylprednisolone—ankylosing spondylitis	0.000157	0.000439	CcSEcCtD
Bortezomib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000157	0.000439	CcSEcCtD
Bortezomib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000157	0.000439	CcSEcCtD
Bortezomib—Infection—Prednisone—ankylosing spondylitis	0.000156	0.000437	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000156	0.000436	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000156	0.000436	CcSEcCtD
Bortezomib—Back pain—Methotrexate—ankylosing spondylitis	0.000155	0.000435	CcSEcCtD
Bortezomib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000155	0.000435	CcSEcCtD
Bortezomib—Fatigue—Betamethasone—ankylosing spondylitis	0.000155	0.000435	CcSEcCtD
Bortezomib—Shock—Prednisone—ankylosing spondylitis	0.000154	0.000433	CcSEcCtD
Bortezomib—PSMB2—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000154	0.000796	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000154	0.000796	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000154	0.000796	CbGpPWpGaD
Bortezomib—Pain—Dexamethasone—ankylosing spondylitis	0.000154	0.000432	CcSEcCtD
Bortezomib—Pain—Betamethasone—ankylosing spondylitis	0.000154	0.000432	CcSEcCtD
Bortezomib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000154	0.000431	CcSEcCtD
Bortezomib—Tachycardia—Prednisone—ankylosing spondylitis	0.000153	0.000429	CcSEcCtD
Bortezomib—Skin disorder—Prednisone—ankylosing spondylitis	0.000152	0.000427	CcSEcCtD
Bortezomib—PSMB8—Adaptive Immune System—HLA-A—ankylosing spondylitis	0.000152	0.000785	CbGpPWpGaD
Bortezomib—Hyperhidrosis—Prednisone—ankylosing spondylitis	0.000152	0.000425	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—ankylosing spondylitis	0.000151	0.000424	CcSEcCtD
Bortezomib—Anorexia—Prednisone—ankylosing spondylitis	0.00015	0.000419	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—ankylosing spondylitis	0.000149	0.000418	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—ankylosing spondylitis	0.000148	0.000416	CcSEcCtD
Bortezomib—Feeling abnormal—Dexamethasone—ankylosing spondylitis	0.000148	0.000416	CcSEcCtD
Bortezomib—Feeling abnormal—Betamethasone—ankylosing spondylitis	0.000148	0.000416	CcSEcCtD
Bortezomib—PSMB1—Immune System—IL1RN—ankylosing spondylitis	0.000148	0.000765	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL1RN—ankylosing spondylitis	0.000148	0.000765	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL1RN—ankylosing spondylitis	0.000148	0.000765	CbGpPWpGaD
Bortezomib—Gastrointestinal pain—Betamethasone—ankylosing spondylitis	0.000147	0.000413	CcSEcCtD
Bortezomib—Gastrointestinal pain—Dexamethasone—ankylosing spondylitis	0.000147	0.000413	CcSEcCtD
Bortezomib—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000146	0.00041	CcSEcCtD
Bortezomib—PSMB8—Immune System—IL1RN—ankylosing spondylitis	0.000146	0.000755	CbGpPWpGaD
Bortezomib—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.000146	0.000409	CcSEcCtD
Bortezomib—Malaise—Methotrexate—ankylosing spondylitis	0.000145	0.000406	CcSEcCtD
Bortezomib—Vertigo—Methotrexate—ankylosing spondylitis	0.000144	0.000404	CcSEcCtD
Bortezomib—PSMB8—Dexamethasone—Methylprednisolone—ankylosing spondylitis	0.000144	0.012	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Methylprednisolone—ankylosing spondylitis	0.000144	0.012	CbGdCrCtD
Bortezomib—Leukopenia—Methotrexate—ankylosing spondylitis	0.000144	0.000403	CcSEcCtD
Bortezomib—Urticaria—Betamethasone—ankylosing spondylitis	0.000143	0.000401	CcSEcCtD
Bortezomib—Urticaria—Dexamethasone—ankylosing spondylitis	0.000143	0.000401	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000143	0.000401	CcSEcCtD
Bortezomib—Dizziness—Prednisolone—ankylosing spondylitis	0.000143	0.0004	CcSEcCtD
Bortezomib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000142	0.000399	CcSEcCtD
Bortezomib—Abdominal pain—Dexamethasone—ankylosing spondylitis	0.000142	0.000399	CcSEcCtD
Bortezomib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000142	0.000399	CcSEcCtD
Bortezomib—Abdominal pain—Betamethasone—ankylosing spondylitis	0.000142	0.000399	CcSEcCtD
Bortezomib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000142	0.000399	CcSEcCtD
Bortezomib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000142	0.000398	CcSEcCtD
Bortezomib—Insomnia—Prednisone—ankylosing spondylitis	0.000142	0.000398	CcSEcCtD
Bortezomib—PSMB8—Betamethasone—Dexamethasone—ankylosing spondylitis	0.000142	0.0119	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Betamethasone—ankylosing spondylitis	0.000142	0.0119	CbGdCrCtD
Bortezomib—Paraesthesia—Prednisone—ankylosing spondylitis	0.000141	0.000395	CcSEcCtD
Bortezomib—PSMA1—Immune System—IL1A—ankylosing spondylitis	0.000141	0.000727	CbGpPWpGaD
Bortezomib—Pruritus—Triamcinolone—ankylosing spondylitis	0.00014	0.000394	CcSEcCtD
Bortezomib—Cough—Methotrexate—ankylosing spondylitis	0.00014	0.000393	CcSEcCtD
Bortezomib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.00014	0.000393	CcSEcCtD
Bortezomib—PSMD1—Immune System—IL1A—ankylosing spondylitis	0.00014	0.000724	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD40LG—ankylosing spondylitis	0.00014	0.000723	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL1A—ankylosing spondylitis	0.000139	0.00072	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD40LG—ankylosing spondylitis	0.000139	0.000719	CbGpPWpGaD
Bortezomib—Convulsion—Methotrexate—ankylosing spondylitis	0.000139	0.00039	CcSEcCtD
Bortezomib—PSMD2—Immune System—CD40LG—ankylosing spondylitis	0.000139	0.000716	CbGpPWpGaD
Bortezomib—PSMB8—Dexamethasone—Triamcinolone—ankylosing spondylitis	0.000139	0.0116	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Triamcinolone—ankylosing spondylitis	0.000139	0.0116	CbGdCrCtD
Bortezomib—Dyspepsia—Prednisone—ankylosing spondylitis	0.000138	0.000387	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000137	0.000383	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—ankylosing spondylitis	0.000137	0.000383	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—ankylosing spondylitis	0.000137	0.000383	CcSEcCtD
Bortezomib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000136	0.000382	CcSEcCtD
Bortezomib—Rash—Prednisolone—ankylosing spondylitis	0.000136	0.000381	CcSEcCtD
Bortezomib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000136	0.000381	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000136	0.000381	CcSEcCtD
Bortezomib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000136	0.00038	CcSEcCtD
Bortezomib—Fatigue—Prednisone—ankylosing spondylitis	0.000135	0.000379	CcSEcCtD
Bortezomib—Headache—Prednisolone—ankylosing spondylitis	0.000135	0.000379	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000135	0.000698	CbGpPWpGaD
Bortezomib—Discomfort—Methotrexate—ankylosing spondylitis	0.000135	0.000379	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000135	0.000695	CbGpPWpGaD
Bortezomib—Constipation—Prednisone—ankylosing spondylitis	0.000134	0.000376	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000134	0.000692	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HLA-B—ankylosing spondylitis	0.000133	0.000688	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HLA-B—ankylosing spondylitis	0.000133	0.000684	CbGpPWpGaD
Bortezomib—Confusional state—Methotrexate—ankylosing spondylitis	0.000132	0.00037	CcSEcCtD
Bortezomib—PSMD2—Immune System—HLA-B—ankylosing spondylitis	0.000132	0.000681	CbGpPWpGaD
Bortezomib—PSMB8—Dexamethasone—Prednisone—ankylosing spondylitis	0.000131	0.011	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisone—ankylosing spondylitis	0.000131	0.011	CbGdCrCtD
Bortezomib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000131	0.000368	CcSEcCtD
Bortezomib—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000131	0.000367	CcSEcCtD
Bortezomib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000131	0.000367	CcSEcCtD
Bortezomib—Infection—Methotrexate—ankylosing spondylitis	0.00013	0.000365	CcSEcCtD
Bortezomib—PSMB1—Immune System—CD79A—ankylosing spondylitis	0.00013	0.000672	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD79A—ankylosing spondylitis	0.00013	0.000672	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD79A—ankylosing spondylitis	0.00013	0.000672	CbGpPWpGaD
Bortezomib—Feeling abnormal—Prednisone—ankylosing spondylitis	0.000129	0.000362	CcSEcCtD
Bortezomib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000129	0.000362	CcSEcCtD
Bortezomib—Asthenia—Betamethasone—ankylosing spondylitis	0.000129	0.000362	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000129	0.00036	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—ankylosing spondylitis	0.000128	0.00036	CcSEcCtD
Bortezomib—PSMB8—Immune System—CD79A—ankylosing spondylitis	0.000128	0.000663	CbGpPWpGaD
Bortezomib—PSMB8—Dexamethasone—Prednisolone—ankylosing spondylitis	0.000128	0.0107	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisolone—ankylosing spondylitis	0.000128	0.0107	CbGdCrCtD
Bortezomib—Gastrointestinal pain—Prednisone—ankylosing spondylitis	0.000128	0.000359	CcSEcCtD
Bortezomib—Nausea—Prednisolone—ankylosing spondylitis	0.000128	0.000359	CcSEcCtD
Bortezomib—Pruritus—Dexamethasone—ankylosing spondylitis	0.000127	0.000357	CcSEcCtD
Bortezomib—Pruritus—Betamethasone—ankylosing spondylitis	0.000127	0.000357	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—ankylosing spondylitis	0.000127	0.000357	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—ankylosing spondylitis	0.000127	0.000355	CcSEcCtD
Bortezomib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000126	0.000354	CcSEcCtD
Bortezomib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000126	0.000353	CcSEcCtD
Bortezomib—Rash—Triamcinolone—ankylosing spondylitis	0.000125	0.000351	CcSEcCtD
Bortezomib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000125	0.00035	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—ankylosing spondylitis	0.000125	0.00035	CcSEcCtD
Bortezomib—Rash—Methylprednisolone—ankylosing spondylitis	0.000125	0.00035	CcSEcCtD
Bortezomib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000125	0.00035	CcSEcCtD
Bortezomib—Urticaria—Prednisone—ankylosing spondylitis	0.000125	0.000349	CcSEcCtD
Bortezomib—Headache—Triamcinolone—ankylosing spondylitis	0.000124	0.000349	CcSEcCtD
Bortezomib—Headache—Methylprednisolone—ankylosing spondylitis	0.000124	0.000348	CcSEcCtD
Bortezomib—Abdominal pain—Prednisone—ankylosing spondylitis	0.000124	0.000348	CcSEcCtD
Bortezomib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000124	0.000348	CcSEcCtD
Bortezomib—PSMA1—Immune System—HLA-A—ankylosing spondylitis	0.000123	0.000637	CbGpPWpGaD
Bortezomib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000123	0.000345	CcSEcCtD
Bortezomib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000123	0.000345	CcSEcCtD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor—TNF—ankylosing spondylitis	0.000123	0.000636	CbGpPWpGaD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—ankylosing spondylitis	0.000123	0.000636	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—HLA-A—ankylosing spondylitis	0.000123	0.000634	CbGpPWpGaD
Bortezomib—Hypotension—Methotrexate—ankylosing spondylitis	0.000123	0.000343	CcSEcCtD
Bortezomib—PSMD2—Immune System—HLA-A—ankylosing spondylitis	0.000122	0.000631	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000119	0.000335	CcSEcCtD
Bortezomib—Dizziness—Betamethasone—ankylosing spondylitis	0.000119	0.000334	CcSEcCtD
Bortezomib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000119	0.000334	CcSEcCtD
Bortezomib—Insomnia—Methotrexate—ankylosing spondylitis	0.000119	0.000332	CcSEcCtD
Bortezomib—Nausea—Triamcinolone—ankylosing spondylitis	0.000118	0.00033	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—ankylosing spondylitis	0.000118	0.00033	CcSEcCtD
Bortezomib—PSMA1—Immune System—CRP—ankylosing spondylitis	0.000118	0.000608	CbGpPWpGaD
Bortezomib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000118	0.00033	CcSEcCtD
Bortezomib—PSMD1—Immune System—CRP—ankylosing spondylitis	0.000117	0.000605	CbGpPWpGaD
Bortezomib—Dyspnoea—Methotrexate—ankylosing spondylitis	0.000117	0.000328	CcSEcCtD
Bortezomib—PSMD2—Immune System—CRP—ankylosing spondylitis	0.000117	0.000602	CbGpPWpGaD
Bortezomib—Hypersensitivity—Prednisone—ankylosing spondylitis	0.000116	0.000324	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—ankylosing spondylitis	0.000115	0.000323	CcSEcCtD
Bortezomib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000115	0.000321	CcSEcCtD
Bortezomib—Vomiting—Betamethasone—ankylosing spondylitis	0.000115	0.000321	CcSEcCtD
Bortezomib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000114	0.000319	CcSEcCtD
Bortezomib—PSMA1—Disease—HLA-A—ankylosing spondylitis	0.000114	0.000588	CbGpPWpGaD
Bortezomib—Rash—Betamethasone—ankylosing spondylitis	0.000114	0.000318	CcSEcCtD
Bortezomib—Rash—Dexamethasone—ankylosing spondylitis	0.000114	0.000318	CcSEcCtD
Bortezomib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000113	0.000318	CcSEcCtD
Bortezomib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000113	0.000318	CcSEcCtD
Bortezomib—PSMD1—Disease—HLA-A—ankylosing spondylitis	0.000113	0.000585	CbGpPWpGaD
Bortezomib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000113	0.000317	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—ankylosing spondylitis	0.000113	0.000317	CcSEcCtD
Bortezomib—Headache—Dexamethasone—ankylosing spondylitis	0.000113	0.000316	CcSEcCtD
Bortezomib—Headache—Betamethasone—ankylosing spondylitis	0.000113	0.000316	CcSEcCtD
Bortezomib—PSMA1—Immune System—TLR4—ankylosing spondylitis	0.000113	0.000583	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HLA-A—ankylosing spondylitis	0.000113	0.000583	CbGpPWpGaD
Bortezomib—Asthenia—Prednisone—ankylosing spondylitis	0.000113	0.000315	CcSEcCtD
Bortezomib—PSMD1—Immune System—TLR4—ankylosing spondylitis	0.000112	0.00058	CbGpPWpGaD
Bortezomib—Pain—Methotrexate—ankylosing spondylitis	0.000112	0.000314	CcSEcCtD
Bortezomib—PSMD2—Immune System—TLR4—ankylosing spondylitis	0.000112	0.000577	CbGpPWpGaD
Bortezomib—Pruritus—Prednisone—ankylosing spondylitis	0.000111	0.000311	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—ankylosing spondylitis	0.000108	0.000303	CcSEcCtD
Bortezomib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000107	0.000301	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—ankylosing spondylitis	0.000107	0.0003	CcSEcCtD
Bortezomib—Nausea—Dexamethasone—ankylosing spondylitis	0.000107	0.0003	CcSEcCtD
Bortezomib—Nausea—Betamethasone—ankylosing spondylitis	0.000107	0.0003	CcSEcCtD
Bortezomib—PSMB5—Immune System—IL1A—ankylosing spondylitis	0.000107	0.000551	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL1A—ankylosing spondylitis	0.000107	0.000551	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL1A—ankylosing spondylitis	0.000107	0.000551	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD40LG—ankylosing spondylitis	0.000106	0.000548	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD40LG—ankylosing spondylitis	0.000106	0.000548	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD40LG—ankylosing spondylitis	0.000106	0.000548	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL1A—ankylosing spondylitis	0.000105	0.000543	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD40LG—ankylosing spondylitis	0.000105	0.00054	CbGpPWpGaD
Bortezomib—Urticaria—Methotrexate—ankylosing spondylitis	0.000104	0.000292	CcSEcCtD
Bortezomib—Dizziness—Prednisone—ankylosing spondylitis	0.000104	0.000291	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—ankylosing spondylitis	0.000104	0.00029	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000104	0.00029	CcSEcCtD
Bortezomib—PSMB1—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000102	0.000529	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000102	0.000529	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000102	0.000529	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTGER4—ankylosing spondylitis	0.000101	0.000522	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HLA-B—ankylosing spondylitis	0.000101	0.000521	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HLA-B—ankylosing spondylitis	0.000101	0.000521	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-B—ankylosing spondylitis	0.000101	0.000521	CbGpPWpGaD
Bortezomib—Vomiting—Prednisone—ankylosing spondylitis	9.98e-05	0.00028	CcSEcCtD
Bortezomib—PSMB8—Immune System—HLA-B—ankylosing spondylitis	9.95e-05	0.000514	CbGpPWpGaD
Bortezomib—Rash—Prednisone—ankylosing spondylitis	9.89e-05	0.000277	CcSEcCtD
Bortezomib—Dermatitis—Prednisone—ankylosing spondylitis	9.88e-05	0.000277	CcSEcCtD
Bortezomib—Headache—Prednisone—ankylosing spondylitis	9.83e-05	0.000275	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—ankylosing spondylitis	9.66e-05	0.000271	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—MMP3—ankylosing spondylitis	9.63e-05	0.000497	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MMP3—ankylosing spondylitis	9.58e-05	0.000495	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MMP3—ankylosing spondylitis	9.54e-05	0.000492	CbGpPWpGaD
Bortezomib—Asthenia—Methotrexate—ankylosing spondylitis	9.41e-05	0.000264	CcSEcCtD
Bortezomib—PSMB2—Immune System—HLA-A—ankylosing spondylitis	9.35e-05	0.000483	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HLA-A—ankylosing spondylitis	9.35e-05	0.000483	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-A—ankylosing spondylitis	9.35e-05	0.000483	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—B3GNT2—ankylosing spondylitis	9.34e-05	0.000482	CbGpPWpGaD
Bortezomib—Nausea—Prednisone—ankylosing spondylitis	9.32e-05	0.000261	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—ankylosing spondylitis	9.28e-05	0.00026	CcSEcCtD
Bortezomib—PSMB8—Immune System—HLA-A—ankylosing spondylitis	9.22e-05	0.000476	CbGpPWpGaD
Bortezomib—Diarrhoea—Methotrexate—ankylosing spondylitis	8.97e-05	0.000251	CcSEcCtD
Bortezomib—PSMB2—Immune System—CRP—ankylosing spondylitis	8.92e-05	0.000461	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CRP—ankylosing spondylitis	8.92e-05	0.000461	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CRP—ankylosing spondylitis	8.92e-05	0.000461	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CRP—ankylosing spondylitis	8.79e-05	0.000454	CbGpPWpGaD
Bortezomib—Dizziness—Methotrexate—ankylosing spondylitis	8.67e-05	0.000243	CcSEcCtD
Bortezomib—PSMB2—Disease—HLA-A—ankylosing spondylitis	8.63e-05	0.000446	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HLA-A—ankylosing spondylitis	8.63e-05	0.000446	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HLA-A—ankylosing spondylitis	8.63e-05	0.000446	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—TLR4—ankylosing spondylitis	8.55e-05	0.000442	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—TLR4—ankylosing spondylitis	8.55e-05	0.000442	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—TLR4—ankylosing spondylitis	8.55e-05	0.000442	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HLA-A—ankylosing spondylitis	8.51e-05	0.000439	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—TLR4—ankylosing spondylitis	8.43e-05	0.000435	CbGpPWpGaD
Bortezomib—Vomiting—Methotrexate—ankylosing spondylitis	8.34e-05	0.000234	CcSEcCtD
Bortezomib—Rash—Methotrexate—ankylosing spondylitis	8.27e-05	0.000232	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—ankylosing spondylitis	8.26e-05	0.000231	CcSEcCtD
Bortezomib—Headache—Methotrexate—ankylosing spondylitis	8.21e-05	0.00023	CcSEcCtD
Bortezomib—Nausea—Methotrexate—ankylosing spondylitis	7.79e-05	0.000218	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—MMP3—ankylosing spondylitis	7.3e-05	0.000377	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP3—ankylosing spondylitis	7.3e-05	0.000377	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP3—ankylosing spondylitis	7.3e-05	0.000377	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP3—ankylosing spondylitis	7.19e-05	0.000371	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—B3GNT2—ankylosing spondylitis	6.58e-05	0.00034	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—B3GNT2—ankylosing spondylitis	6.03e-05	0.000312	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—B3GNT2—ankylosing spondylitis	5.39e-05	0.000278	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—B3GNT2—ankylosing spondylitis	4.95e-05	0.000256	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—B3GNT2—ankylosing spondylitis	4.91e-05	0.000254	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—B3GNT2—ankylosing spondylitis	4.2e-05	0.000217	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—B3GNT2—ankylosing spondylitis	3.24e-05	0.000167	CbGpPWpGaD
